Edition:
United States

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

0.25USD
14 Dec 2018
Change (% chg)

$-0.01 (-3.18%)
Prev Close
$0.26
Open
$0.27
Day's High
$0.29
Day's Low
$0.25
Volume
10,511
Avg. Vol
38,460
52-wk High
$3.08
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Bio-Path Holdings reports third quarter results
Thursday, 15 Nov 2018 07:00am EST 

Nov 15 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH OF $2.3 MILLION, COMPARED TO $6.0 MILLION AT DECEMBER 31, 2017.  Full Article

Bio-Path Holdings Announces $1.5 Mln Registered Direct Offering
Friday, 21 Sep 2018 06:30am EDT 

Sept 21 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES $1.5 MILLION REGISTERED DIRECT OFFERING.BIO PATH HOLDINGS - ENTERED INTO DEFINITIVE AGREEMENTS WITH SEVERAL HEALTHCARE FOCUSED INVESTORS FOR SALE OF 2.3 MILLION SHARES FOR $0.65 PER SHARE.  Full Article

Bio-Path Holdings Reports Full Year 2017 Financial Results
Tuesday, 3 Apr 2018 07:30am EDT 

April 3 (Reuters) - Bio Path Holdings Inc ::PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULTS.  Full Article

Bio-Path Holdings Announces Interim Data From Phase 2 Clinical Trial Of Prexigebersen
Tuesday, 3 Apr 2018 07:15am EDT 

April 3 (Reuters) - Bio Path Holdings Inc ::PATH HOLDINGS ANNOUNCES INTERIM DATA FROM PHASE 2 CLINICAL TRIAL OF PREXIGEBERSEN IN COMBINATION WITH LOW DOSE CYTARABINE (LDAC) FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML).BIO PATH HOLDINGS INC - PREXIGEBERSEN PLUS LDAC WAS WELL-TOLERATED.LEUKEMIC ACTIVITY IN NEARLY 50% OF EVALUABLE AML PATIENTS TREATED TO DATE​.‍ AMENDING PROTOCOL TO CHANGE DOSING SCHEDULE TO THAT USED IN PHASE 1B STUDY IN RELAPSED AND REFRACTORY AML PATIENTS​.  Full Article

Bio-Path Holdings Announces 1-For-10 Reverse Stock Split
Friday, 9 Feb 2018 07:00am EST 

Feb 9 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.BIO PATH HOLDINGS - REVERSE STOCK SPLIT BECAME EFFECTIVE AT 5:00 PM EASTERN TIME ON FEBRUARY 8, 2018.  Full Article

Bio-Path Holdings Q3 loss per share $0.02
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Bio Path Holdings Inc ::Bio-Path Holdings reports third quarter 2017 financial results.Q3 loss per share $0.02.  Full Article

Bio-Path Holdings announces $4 mln registered direct offering
Friday, 3 Nov 2017 09:20am EDT 

Nov 3 (Reuters) - Bio Path Holdings Inc :Bio-Path Holdings, Inc. Announces $4 million registered direct offering.Bio Path Holdings Inc - ‍offering of 13.3 million shares of common stock and warrants to purchase up to 6.7 million shares of common stock​.Bio Path Holdings Inc- ‍offering price per share of common stock and one-half warrant is $0.30​.  Full Article

Bio Path Holdings says plans to add a new CFO with significant financial experience
Tuesday, 20 Jun 2017 09:02am EDT 

June 20 (Reuters) - Bio Path Holdings Inc :Says plans to add a new CFO with significant financial experience - sec filing.  Full Article

Bio Path Holdings reports Q1 loss per share of $0.01
Thursday, 11 May 2017 07:00am EDT 

May 11 (Reuters) - Bio Path Holdings Inc :Bio-Path Holdings reports first quarter 2017 financial results.Q1 loss per share $0.01.Research and development expenses for both three months ended March 31, 2017 and March 31, 2016, were $1.0 million.As of March 31, 2017, company had cash of $7.1 million, compared to $9.4 million at December 31, 2016.  Full Article

  • Previous
  • Next

Bio Path Holdings Inc News

» More BPTH.OQ News

Earnings vs. Estimates

» More Financials